

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS AND
INDEPENDENT AUDITORS' REVIEW REPORT
SEPTEMBER 30, 2025 AND 2024

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
SEPTEMBER 30, 2025 AND 2024 CONSOLIDATED FINANCIAL STATEMENTS
AND INDEPENDENT AUDITORS' REVIEW REPORT
TABLE OF CONTENTS

Contents	Page
1. Cover Page	1
2. Table of Contents	2 ~ 3
3. Independent Auditors' Review Report	4 ~ 6
4. Consolidated Balance Sheets	7 ~ 8
5. Consolidated Statements of Comprehensive Income	9
6. Consolidated Statements of Changes in Equity	10
7. Consolidated Statements of Cash Flows	11 ~ 12
8. Notes to the Consolidated Financial Statements	13 ~ 54
(1) HISTORY AND ORGANISATION	13
(2) THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION	13
(3) APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS	13 ~ 14
(4) SUMMARY OF MATERIAL ACCOUNTING POLICIES	15 ~ 16
(5) CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND	16

Contents	Page
KEY SOURCES OF ASSUMPTION UNCERTAINTY	
(6) DETAILS OF SIGNIFICANT ACCOUNTS	17 ~ 41
(7) RELATED PARTY TRANSACTIONS	41 ~ 42
(8) PLEDGED ASSETS	42
(9) SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS	43
(10) SIGNIFICANT DISASTER LOSS	43
(11) SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE	43
(12) OTHERS	43 ~ 52
(13) SUPPLEMENTARY DISCLOSURES	52
A. Significant transactions information	52
B. Information on investees	52
C. Information on investments in Mainland China	52
(14) SEGMENT INFORMATION	52 ~ 54

INDEPENDENT AUDITORS' REVIEW REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of ScinoPharm Taiwan, Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of ScinoPharm Taiwan, Ltd. and subsidiaries (the "Group") as at September 30, 2025 and 2024, and the related consolidated statements of comprehensive income for the three-month and nine-month periods then ended, as well as the consolidated statements of changes in equity and of cash flows for the nine-month periods then ended, and notes to the consolidated financial statements, including a summary of material accounting policies. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" that came into effect as endorsed by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of review

Except as explained in the following paragraph, we conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for qualified conclusion

The financial statements of certain insignificant consolidated subsidiaries and supplementary disclosures in Note 13 were not reviewed by independent auditors. Those statements reflect total assets of \$18,059 thousand and \$28,612 thousand, both constituting —% of the consolidated total assets, and total liabilities of \$973 thousand and \$9,576 thousand, constituting —% and 1% of the consolidated total liabilities as at September 30, 2025 and 2024, respectively, and total comprehensive income (loss) of \$1,148 thousand, \$553 thousand, (\$304) thousand and \$2,022 thousand, constituting —%, 1%, —% and 1% of the consolidated total comprehensive income for the three-month and nine-month periods then ended, respectively.

Qualified conclusion

Except for the adjustments to the consolidated financial statements, if any, as might have been determined to be necessary had the financial statements of certain insignificant subsidiaries and supplementary disclosures in Note 13 been reviewed by independent auditors as described in the Basis for qualified conclusion section above, based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as at September 30, 2025 and 2024, and its consolidated financial performance for the three-month and nine-month periods then ended and its consolidated cash flows for the nine-month periods then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” that came into effect as endorsed by the Financial Supervisory Commission.

Yeh, Fang-Ting

Independent Auditors

Hsu, Hui-Yu

PricewaterhouseCoopers, Taiwan

Republic of China

November 3, 2025

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2025, DECEMBER 31, 2024 AND SEPTEMBER 30, 2024
(Expressed in thousands of New Taiwan dollars)

Assets		Notes	September 30, 2025		December 31, 2024		September 30, 2024	
			AMOUNT	%	AMOUNT	%	AMOUNT	%
Current assets								
1100	Cash and cash equivalents	6(1)	\$ 2,850,745	23	\$ 4,165,987	35	\$ 3,975,691	34
1110	Financial assets at fair value	6(2)						
	through profit or loss - current		-	-	-	-	1,974	-
1140	Contract assets - current	6(17)	77,480	1	29,397	-	-	-
1170	Accounts receivable, net	6(3) and 12	378,726	3	604,219	5	445,565	4
1200	Other receivables		22,502	-	20,572	-	29,346	-
130X	Inventories	6(4)	1,904,457	16	1,673,007	14	1,876,599	16
1410	Prepayments		178,499	1	114,908	1	157,927	1
11XX	Total current assets		<u>5,412,409</u>	<u>44</u>	<u>6,608,090</u>	<u>55</u>	<u>6,487,102</u>	<u>55</u>
Non-current assets								
1517	Financial assets at fair value	6(5)						
	through other comprehensive							
	income - non-current		1,952,113	16	70,134	1	74,564	1
1600	Property, plant and equipment	6(6)(8) and 7	3,423,328	28	3,738,889	32	3,702,367	32
1755	Right-of-use assets	6(7)	676,471	5	686,635	6	688,527	6
1780	Intangible assets	6(6)	16,761	-	17,130	-	22,614	-
1840	Deferred income tax assets	6(24)	649,229	5	625,260	5	637,515	5
1915	Prepayments for equipment	6(6)	87,827	1	150,890	1	138,290	1
1920	Guarantee deposits paid		2,995	-	2,367	-	2,385	-
1980	Other financial assets - non-	6(1) and 8						
	current		29,270	-	30,940	-	30,940	-
1990	Other non-current assets	6(6)	61,546	1	12,403	-	-	-
15XX	Total non-current assets		<u>6,899,540</u>	<u>56</u>	<u>5,334,648</u>	<u>45</u>	<u>5,297,202</u>	<u>45</u>
1XXX	Total assets		<u>\$ 12,311,949</u>	<u>100</u>	<u>\$ 11,942,738</u>	<u>100</u>	<u>\$ 11,784,304</u>	<u>100</u>

(Continued)

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2025, DECEMBER 31, 2024 AND SEPTEMBER 30, 2024
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity		Notes	September 30, 2025		December 31, 2024		September 30, 2024	
			AMOUNT	%	AMOUNT	%	AMOUNT	%
Current liabilities								
2100	Short-term borrowings	6(9)	\$ 139,477	1	\$ 35,563	-	\$ 35,704	-
2120	Financial liabilities at fair value	6(2)						
	through profit or loss - current		2,107	-	1,225	-	-	-
2130	Contract liabilities - current	6(17)	75,940	1	119,396	1	157,755	2
2150	Notes payable		-	-	1,211	-	1,603	-
2170	Accounts payable		112,017	1	80,959	1	126,966	1
2200	Other payables	6(10)	314,652	3	498,191	4	341,918	3
2230	Current income tax liabilities	6(24)	21,627	-	11,499	-	11,803	-
2280	Lease liabilities - current		23,797	-	19,638	-	18,286	-
21XX	Total current liabilities		<u>689,617</u>	<u>6</u>	<u>767,682</u>	<u>6</u>	<u>694,035</u>	<u>6</u>
Non-current liabilities								
2570	Deferred income tax liabilities	6(24)	1,625	-	1,304	-	395	-
2580	Lease liabilities - non-current		612,627	5	620,342	5	622,136	5
2640	Net defined benefit liabilities -	6(11)						
	non-current		11,436	-	23,614	1	23,489	-
2645	Guarantee deposits received		3,698	-	3,992	-	4,343	-
25XX	Total non-current liabilities		<u>629,386</u>	<u>5</u>	<u>649,252</u>	<u>6</u>	<u>650,363</u>	<u>5</u>
2XXX	Total liabilities		<u>1,319,003</u>	<u>11</u>	<u>1,416,934</u>	<u>12</u>	<u>1,344,398</u>	<u>11</u>
Equity attributable to owners of parent								
	Share capital	6(12)						
3110	Common stock		7,907,392	64	7,907,392	66	7,907,392	67
3200	Capital surplus	6(13)	1,294,689	10	1,294,689	10	1,294,689	11
	Retained earnings	6(15)						
3310	Legal reserve		817,709	7	783,817	7	783,817	7
3320	Special reserve		126,177	1	185,856	2	185,856	2
3350	Unappropriated earnings		324,925	3	480,227	4	383,318	3
3400	Other equity interest	6(16)	522,054	4	(126,177)	(1)	(115,166)	(1)
3XXX	Total equity		<u>10,992,946</u>	<u>89</u>	<u>10,525,804</u>	<u>88</u>	<u>10,439,906</u>	<u>89</u>
	Significant contingent liabilities	9						
	and unrecognised contract commitments							
3X2X	Total liabilities and equity		<u>\$ 12,311,949</u>	<u>100</u>	<u>\$ 11,942,738</u>	<u>100</u>	<u>\$ 11,784,304</u>	<u>100</u>

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars, except for earnings per share amount)

	Items	Notes	Three months ended September 30				Nine months ended September 30			
			2025		2024		2025		2024	
			AMOUNT	%	AMOUNT	%	AMOUNT	%	AMOUNT	%
4000	Operating revenue	6(17)	\$ 721,495	100	\$ 724,223	100	\$ 2,155,381	100	\$ 2,369,808	100
5000	Operating costs	6(4)(11)(22)(23)	(505,661)	(70)	(445,235)	(61)	(1,392,015)	(64)	(1,446,744)	(61)
5900	Net operating margin		215,834	30	278,988	39	763,366	36	923,064	39
	Operating expenses	6(7)(11)(22)(23), 7 and 12								
6100	Selling expenses		(26,365)	(4)	(29,236)	(4)	(87,425)	(4)	(109,892)	(5)
6200	General and administrative expenses		(87,666)	(12)	(80,819)	(11)	(274,750)	(13)	(266,460)	(11)
6300	Research and development expenses		(121,397)	(17)	(135,971)	(19)	(302,108)	(14)	(290,211)	(12)
6450	Expected credit gain (loss)		(24)	-	(1,126)	-	1,790	-	(1,681)	-
6000	Total operating expenses		(235,452)	(33)	(247,152)	(34)	(662,493)	(31)	(668,244)	(28)
6900	Operating profit		(19,618)	(3)	31,836	5	100,873	5	254,820	11
	Non-operating income and expenses									
7100	Interest income	6(18)	12,009	2	15,064	2	41,125	2	45,238	2
7010	Other income	6(5)(19)	26,725	4	2,376	-	27,602	1	4,446	-
7020	Other gains and losses	6(2)(8)(20) and 12	2,770	-	(13,405)	(2)	(39,080)	(2)	722	-
7050	Finance costs	6(7)(21)	(2,708)	-	(1,934)	-	(7,108)	-	(6,001)	-
7000	Total non-operating income and expenses		38,796	6	2,101	-	22,539	1	44,405	2
7900	Profit before income tax		19,178	3	33,937	5	123,412	6	299,225	13
7950	Income tax expense	6(24)	(3,732)	(1)	(6,834)	(1)	(27,742)	(1)	(57,217)	(3)
8200	Profit for the period		<u>\$ 15,446</u>	<u>2</u>	<u>\$ 27,103</u>	<u>4</u>	<u>\$ 95,670</u>	<u>5</u>	<u>\$ 242,008</u>	<u>10</u>
	Other comprehensive income (loss)									
	Components of other comprehensive income (loss) that will not be reclassified to profit or loss									
8316	Unrealised gain from equity instruments measured at fair value through other comprehensive income	6(5)(16)	\$ 645,514	89	\$ 25,202	3	\$ 725,979	34	\$ 4,591	-
	Components of other comprehensive income (loss) that will be reclassified to profit or loss									
8361	Financial statements translation differences of foreign operations	6(16)	63,527	9	15,637	2	(77,748)	(4)	66,099	3
8300	Total other comprehensive income for the period		<u>\$ 709,041</u>	<u>98</u>	<u>\$ 40,839</u>	<u>5</u>	<u>\$ 648,231</u>	<u>30</u>	<u>\$ 70,690</u>	<u>3</u>
8500	Total comprehensive income for the period		<u>\$ 724,487</u>	<u>100</u>	<u>\$ 67,942</u>	<u>9</u>	<u>\$ 743,901</u>	<u>35</u>	<u>\$ 312,698</u>	<u>13</u>
	Profit attributable to:									
8610	Owners of the parent		<u>\$ 15,446</u>	<u>2</u>	<u>\$ 27,103</u>	<u>4</u>	<u>\$ 95,670</u>	<u>5</u>	<u>\$ 242,008</u>	<u>10</u>
	Comprehensive income attributable to:									
8710	Owners of the parent		<u>\$ 724,487</u>	<u>100</u>	<u>\$ 67,942</u>	<u>9</u>	<u>\$ 743,901</u>	<u>35</u>	<u>\$ 312,698</u>	<u>13</u>
	Earnings per share (in dollars)	6(25)								
9750	Basic		\$ 0.02		\$ 0.03		\$ 0.12		\$ 0.31	
9850	Diluted		\$ 0.02		\$ 0.03		\$ 0.12		\$ 0.31	

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

		Equity attributable to owners of the parent							
		Retained Earnings				Other Equity Interest			
						Financial statements translation differences of foreign operations		Unrealised (losses) gains from financial assets measured at fair value through other comprehensive income	
Notes		Share capital - common stock	Capital reserve	Legal reserve	Special reserve	Unappropriated earnings			Total equity
<u>Nine months ended September 30, 2024</u>									
		\$ 7,907,392	\$ 1,294,689	\$ 755,145	\$ 98,176	\$ 494,884	(\$ 88,156)	(\$ 97,700)	\$ 10,364,430
		-	-	-	-	242,008	-	-	242,008
Other comprehensive income for the nine-month period ended September 30, 2024	6(5)(16)	-	-	-	-	-	66,099	4,591	70,690
Total comprehensive income for the nine-month period ended September 30, 2024		-	-	-	-	242,008	66,099	4,591	312,698
Distribution of 2023 net income:									
		-	-	28,672	-	(28,672)	-	-	-
		-	-	-	87,680	(87,680)	-	-	-
Cash dividends	6(15)	-	-	-	-	(237,222)	-	-	(237,222)
Balance at September 30, 2024		\$ 7,907,392	\$ 1,294,689	\$ 783,817	\$ 185,856	\$ 383,318	(\$ 22,057)	(\$ 93,109)	\$ 10,439,906
<u>Nine months ended September 30, 2025</u>									
		\$ 7,907,392	\$ 1,294,689	\$ 783,817	\$ 185,856	\$ 480,227	(\$ 28,638)	(\$ 97,539)	\$ 10,525,804
		-	-	-	-	95,670	-	-	95,670
Other comprehensive (loss) income for the nine-month period ended September 30, 2025	6(5)(16)	-	-	-	-	-	(77,748)	725,979	648,231
Total comprehensive income (loss) for the nine-month period ended September 30, 2025		-	-	-	-	95,670	(77,748)	725,979	743,901
Distribution of 2024 net income:									
		-	-	33,892	-	(33,892)	-	-	-
Cash dividends	6(15)	-	-	-	-	(276,759)	-	-	(276,759)
Reversal of special reserve		-	-	-	(59,679)	59,679	-	-	-
Balance at September 30, 2025		\$ 7,907,392	\$ 1,294,689	\$ 817,709	\$ 126,177	\$ 324,925	(\$ 106,386)	\$ 628,440	\$ 10,992,946

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

	Notes	Nine months ended September 30 2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		\$ 123,412	\$ 299,225
Adjustments			
Adjustments to reconcile profit (loss)			
Loss on valuation of financial assets and liabilities at fair value through profit or loss		882	6,330
Expected credit (gain) loss	12	(1,790)	1,681
Loss on inventory market price decline	6(4)	44,982	40,049
Depreciation of property, plant and equipment	6(6)(22)	354,809	345,001
Depreciation of right-of-use assets	6(7)(22)	15,288	12,928
(Gain) loss on disposal of property, plant and equipment	6(20)	(3)	4,278
Gain on reversal of impairment loss	6(6)(8)(20)	(63)	-
Amortisation	6(22)	15,247	6,876
Interest income	6(18)	(41,125)	(45,238)
Dividend income	6(5)(19)	(25,615)	-
Interest expense	6(21)	7,108	6,001
Changes in operating assets and liabilities			
Changes in operating assets			
Contract assets - current		(48,083)	-
Accounts receivable		227,283	340,970
Other receivables		(4,300)	(2,809)
Inventories		(275,820)	(408,513)
Prepayments		(60,460)	(51,503)
Changes in operating liabilities			
Contract liabilities - current		(43,456)	46,788
Notes payable		(1,211)	424
Accounts payable		31,058	25,688
Other payables		(69,997)	(37,101)
Net defined benefit liabilities - non-current		(12,178)	(31,025)
Cash inflow generated from operations		235,968	560,050
Interest received		43,495	43,931
Dividends received		25,615	-
Interest paid		(7,010)	(5,997)
Income tax paid		(46,134)	(101,714)
Net cash flows from operating activities		251,934	496,270

(Continued)

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

	Notes	Nine months ended September 30 2025	2024
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of financial assets at fair value through other comprehensive income - non-current		(\$ 1,156,000)	\$ -
Cash paid for acquisition of property, plant and equipment	6(26)	(113,085)	(88,675)
Proceeds from disposal of property, plant and equipment		1,218	6,204
Acquisition of intangible assets		(4,610)	(9,980)
Cash paid for prepayments for equipment	6(26)	(96,196)	(141,979)
(Increase) decrease in guarantee deposits paid		(701)	8
Decrease in other financial assets - non-current		1,670	-
Increase in other assets - non-current		(1,737)	-
Net cash flows used in investing activities		(1,369,441)	(234,422)
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Increase in short-term borrowings	6(27)	140,839	35,250
Decrease in short-term borrowings	6(27)	(34,175)	(33,084)
Repayment of the principal portion of lease liabilities	6(27)	(11,797)	(9,350)
(Decrease) increase in guarantee deposits received	6(27)	(181)	2,974
Payment of cash dividends	6(15)	(276,759)	(237,222)
Net cash flows used in financing activities		(182,073)	(241,432)
Effect of foreign exchange rate changes		(15,662)	13,751
Net (decrease) increase in cash and cash equivalents		(1,315,242)	34,167
Cash and cash equivalents at beginning of period	6(1)	4,165,987	3,941,524
Cash and cash equivalents at end of period	6(1)	\$ 2,850,745	\$ 3,975,691

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTHS PERIODS ENDED SEPTEMBER 30, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. HISTORY AND ORGANISATION

- (1) ScinoPharm Taiwan, Ltd. (the “Company”) was incorporated as a company limited by shares under the provisions of the Company Act of the Republic of China (R.O.C.) on November 11, 1997. The Company and its subsidiaries (the “Group”) are primarily engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade and research, development, production, manufacture and sales of Active Pharmaceutical Ingredients (“API”), albumin medicines, oligonucleotide medicines, peptide medicines, injections and new small molecule drugs, as well as the provision of related consulting and technical services and international trade for the above products. In addition, the Company sells the chemical material which is reprocessed from the material recycled from the Company’s manufacturing process. For more information regarding the manufacturing and trading activities the Group are engaged in, refer to Note 4(3), “Basis of consolidation”.
- (2) The common shares of the Company have been listed on the Taiwan Stock Exchange since September 2011.
- (3) Uni-President Enterprises Corp., the Company’s ultimate parent company, holds 37.94% equity interest in the Company.

2. THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION

These consolidated financial statements were authorised for issuance by the Board of Directors on November 3, 2025.

3. APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS

- (1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS[®]”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by the FSC and became effective from 2025 are as follows:

<u>New Standards, Interpretations and Amendments</u>	<u>Effective date by International Accounting Standards Board (“IASB”)</u>
Amendments to IAS 21, ‘Lack of Exchangeability’	January 1, 2025

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC effective from 2026 are as follows:

New Standards, Interpretations and Amendments	Effective date by IASB
Specific provisions of Amendments to IFRS 9 and IFRS 7, 'Amendments to the classification and measurement of financial instruments'	January 1, 2026
Amendments to IFRS 9 and IFRS 7, 'Contracts referencing nature-dependent electricity'	January 1, 2026
IFRS 17, 'Insurance contracts'	January 1, 2023
Amendments to IFRS 17, 'Insurance contracts'	January 1, 2023
Amendment to IFRS 17, 'Initial application of IFRS 17 and IFRS 9 – comparative information'	January 1, 2023
Annual Improvements to IFRS Accounting Standards – Volume 11	January 1, 2026

The above standards and interpretations have no significant impact to the Group's financial condition and financial performance based on the Group's assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

New Standards, Interpretations and Amendments	Effective date by IASB
Amendments to IFRS 10 and IAS 28, 'Sale or contribution of assets between an investor and its associate or joint venture'	To be determined by IASB
IFRS 18, 'Presentation and disclosure in financial statements'	January 1, 2027 (Note)
IFRS 19, 'Subsidiaries without public accountability: disclosures'	January 1, 2027

Note : The FSC has announced in a press release on September 25, 2025 that public companies will apply IFRS 18 starting from the fiscal year 2028. Additionally, entities can choose to adopt IFRS 18 earlier based on their requirements after the FSC endorses IFRS 18.

Except for the following, the above standards and interpretations have no significant impact to the Group's financial condition and financial performance based on the Group's assessment.

IFRS 18, 'Presentation and disclosure in financial statements'

IFRS 18, 'Presentation and disclosure in financial statements' replaces IAS 1. The standard introduces a defined structure of the statement of profit or loss, disclosure requirements related to management-defined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

Except for the compliance statement, basis of preparation, basis of consolidation and applicable policies of the interim financial statements as set out below, the other principal accounting policies are in agreement with Note 4 of the consolidated financial statements for the year ended December 31, 2024. These policies have been consistently applied to all the periods presented, unless otherwise stated.

(1) Compliance statement

- A. The consolidated financial statements of the Group have been prepared in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers”, and IAS 34, ‘Interim Financial Reporting’ that came into effect as endorsed by the FSC.
- B. The consolidated financial statements should be read together with the consolidated financial statements for the year ended December 31, 2024.

(2) Basis of preparation

- A. Except for the following items, these consolidated financial statements have been prepared under the historical cost convention:
 - (a) Financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.
 - (b) Financial assets at fair value through other comprehensive income.
 - (c) Defined benefit liabilities recognised based on the net amount of pension fund assets less present value of defined benefit obligation.
- B. The preparation of financial statements in conformity with International Financial Reporting Standards, International Accounting Standards, IFRIC[®] Interpretations and SIC[®] Interpretations that came into effect as endorsed by the FSC (collectively referred herein as the “IFRSs”) requires that use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

(3) Basis of consolidation

- A. Basis for preparation of consolidated financial statements:

The basis for preparation of these consolidated financial statements is consistent with those for the preparation of consolidated financial statements for the year ended December 31, 2024.

- B. Subsidiaries included in the consolidated financial statements:

Name of Investors	Name of Subsidiaries	Business Activities	Percentage owned by the Company			Note
			September 30, 2025	December 31, 2024	September 30, 2024	
ScinoPharm Taiwan, Ltd.	SPT International, Ltd.	Professional investment	100.00	100.00	100.00	—

Name of Investors	Name of Subsidiaries	Business Activities	Percentage owned by the Company			Note
			September 30, 2025	December 31, 2024	September 30, 2024	
ScinoPharm Taiwan, Ltd.	ScinoPharm Singapore Pte Ltd.	Professional investment	100.00	100.00	100.00	(Note)
SPT International, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	Research, development and manufacture of API and new drugs, sales of self-produced products, etc.	100.00	100.00	100.00	—
SPT International, Ltd.	SciAnda Shanghai Biochemical Technology, Ltd.	Import, export and sales of API and intermediates, etc.	100.00	100.00	100.00	(Note)

Note : The financial statements of the entity as of and for the nine-month periods ended September 30, 2025 and 2024 were not reviewed by independent auditors as the entity did not meet the definition of a significant subsidiary.

C. Subsidiaries not included in the consolidated financial statements: None.

D. Adjustments for subsidiaries with different balance sheet dates: None.

E. Significant restrictions: None.

F. Subsidiaries that have non-controlling interests that are material to the Group: None.

(4) Employee benefits

Defined benefit plans

Pension cost for the interim period is calculated on a year-to-date basis by using the pension cost rate derived from the actuarial valuation at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events. Also, the related information is disclosed accordingly.

(5) Income tax

The interim period income tax expense is recognised based on the estimated average annual effective income tax rate expected for the full financial year applied to the pretax income of the interim period, and the related information is disclosed accordingly.

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

There have been no significant changes during the period. Refer to Note 5 of the consolidated financial statements for the year ended December 31, 2024.

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) CASH AND CASH EQUIVALENTS

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
Cash:			
Cash on hand	\$ 119	\$ 129	\$ 128
Checking accounts and demand deposits	<u>102,126</u>	<u>167,117</u>	<u>237,063</u>
	<u>102,245</u>	<u>167,246</u>	<u>237,191</u>
Cash equivalents:			
Time deposits	2,648,500	3,833,741	3,648,500
Bills under repurchase agreements	<u>100,000</u>	<u>165,000</u>	<u>90,000</u>
	<u>2,748,500</u>	<u>3,998,741</u>	<u>3,738,500</u>
	<u>\$ 2,850,745</u>	<u>\$ 4,165,987</u>	<u>\$ 3,975,691</u>

- A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.
- B. Details of the Group's time deposits pledged to others as collateral (listed as "Other financial assets - non-current") as of September 30, 2025, December 31, 2024, and September 30, 2024 are provided in Note 8, "Pledged assets".

(2) FINANCIAL ASSETS AND LIABILITIES AT FAIR VALUE THROUGH PROFIT OR LOSS

<u>Items</u>	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
Current items:			
Financial (liabilities) assets mandatorily measured at fair value through profit or loss			
Derivatives	<u>(\$ 2,107)</u>	<u>(\$ 1,225)</u>	<u>\$ 1,974</u>
Non-current items:			
Financial assets mandatorily measured at fair value through profit or loss			
Unlisted stocks	\$ 4,620	\$ 4,620	\$ 4,620
Valuation adjustment	<u>(4,620)</u>	<u>(4,620)</u>	<u>(4,620)</u>
	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

- A. The Group recognised net (loss) gain of (\$9,939), \$1,506, \$2,884 and (\$21,178) on financial assets and liabilities at fair value through profit or loss (listed as "Other gains and losses") for the three-month and nine-month periods ended September 30, 2025 and 2024, respectively.

B. The Group entered into contracts relating to derivative financial assets and liabilities which were not accounted for under hedge accounting. The information is listed below (Units in thousands of currencies indicated):

		September 30, 2025	
Items		Contract amount	Contract period
Forward foreign exchange contracts	USD	7,200	7.2025~11.2025

		December 31, 2024	
Items		Contract amount	Contract period
Forward foreign exchange contracts	USD	7,830	11.2024~2.2025

		September 30, 2024	
Items		Contract amount	Contract period
Forward foreign exchange contracts	USD	6,360	8.2024~11.2024

The Group entered into forward foreign exchange contracts to hedge exchange rate risk of operating activities. However, these forward foreign exchange contracts are not accounted for under hedge accounting.

C. The Group has no financial assets at fair value through profit or loss pledged to others as of September 30, 2025, December 31, 2024, and September 30, 2024.

(3) ACCOUNTS RECEIVABLE, NET

	September 30, 2025	December 31, 2024	September 30, 2024
Accounts receivable	\$ 378,840	\$ 606,123	\$ 447,482
Less: Loss allowance	(114)	(1,904)	(1,917)
	<u>\$ 378,726</u>	<u>\$ 604,219</u>	<u>\$ 445,565</u>

A. The ageing analysis of accounts receivable is as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Not past due	\$ 309,450	\$ 509,007	\$ 332,958
Less than 30 days	43,949	94,992	81,468
Between 31 to 90 days	25,350	308	30,987
Between 91 to 180 days	91	-	316
Over 181 days	-	1,816	1,753
	<u>\$ 378,840</u>	<u>\$ 606,123</u>	<u>\$ 447,482</u>

The above ageing analysis is based on past due date.

B. As of September 30, 2025, December 31, 2024, and September 30, 2024, accounts receivable arose from contracts with customers. As of January 1, 2024, the balance of receivables from contracts with customers amounted to \$788,452.

C. As of September 30, 2025, December 31, 2024, and September 30, 2024, the Group does not hold any collateral as security.

D. As of September 30, 2025, December 31, 2024, and September 30, 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Group's notes and accounts receivable was the book value amount.

E. Information relating to credit risk of accounts receivable is provided in Note 12(2), "Financial instruments".

(4) INVENTORIES

September 30, 2025			
	Cost	Allowance for market price decline	Book value
Raw materials	\$ 348,503	(\$ 61,673)	\$ 286,830
Supplies	92,812	(3,571)	89,241
Work in process	632,807	(105,264)	527,543
Finished goods	1,287,036	(286,193)	1,000,843
	<u>\$ 2,361,158</u>	<u>(\$ 456,701)</u>	<u>\$ 1,904,457</u>
December 31, 2024			
	Cost	Allowance for market price decline	Book value
Raw materials	\$ 375,907	(\$ 64,953)	\$ 310,954
Supplies	51,867	(4,639)	47,228
Work in process	658,527	(85,105)	573,422
Finished goods	1,002,857	(261,454)	741,403
	<u>\$ 2,089,158</u>	<u>(\$ 416,151)</u>	<u>\$ 1,673,007</u>
September 30, 2024			
	Cost	Allowance for market price decline	Book value
Raw materials	\$ 380,299	(\$ 71,014)	\$ 309,285
Supplies	55,655	(4,645)	51,010
Work in process	645,705	(101,430)	544,275
Finished goods	1,241,463	(269,434)	972,029
	<u>\$ 2,323,122</u>	<u>(\$ 446,523)</u>	<u>\$ 1,876,599</u>

The cost of inventories recognised as expense for the period:

	For the three-month periods ended September 30,	
	2025	2024
Cost of goods sold	\$ 313,383	\$ 292,118
Loss on physical inventory	144	156
Under applied manufacturing overhead	127,704	114,903
Loss on inventory market price decline	17,307	17,958
Revenue from sale of scraps	(512)	(462)
	<u>\$ 458,026</u>	<u>\$ 424,673</u>
	For the nine-month periods ended September 30,	
	2025	2024
Cost of goods sold	\$ 926,396	\$ 1,057,298
Loss on scrap inventory	3,324	-
Loss on physical inventory	380	559
Under applied manufacturing overhead	345,974	316,862
Loss on inventory market price decline	44,982	40,049
Revenue from sale of scraps	(1,551)	(1,375)
	<u>\$ 1,319,505</u>	<u>\$ 1,413,393</u>

(5) FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME - NON-CURRENT

Items	September 30, 2025	December 31, 2024	September 30, 2024
Equity instruments			
Emerging stocks	\$ 1,156,000	\$ -	\$ -
Unlisted stocks	<u>167,673</u>	<u>167,673</u>	<u>167,673</u>
	1,323,673	167,673	167,673
Valuation adjustment	<u>628,440</u>	(97,539)	(93,109)
	<u>\$ 1,952,113</u>	<u>\$ 70,134</u>	<u>\$ 74,564</u>

A. The Group has elected to classify investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments is the book value as of September 30, 2025, December 31, 2024, and September 30, 2024.

B. Amounts recognised in other comprehensive income in relation to the financial assets at fair value through other comprehensive income are listed below:

Equity instruments at fair value through other comprehensive income	For the three-month periods ended September 30,	
	2025	2024
Fair value change recognised in other comprehensive income	<u>\$ 645,514</u>	<u>\$ 25,202</u>
Dividend income recognised in profit or loss	<u>\$ 25,615</u>	<u>\$ -</u>

Equity instruments at fair value through other comprehensive income	For the nine-month periods ended September 30,	
	2025	2024
Fair value change recognised in other comprehensive income	\$ 725,979	\$ 4,591
Dividend income recognised in profit or loss	\$ 25,615	\$ -

- C. The Group has no financial assets at fair value through other comprehensive income pledged to others as of September 30, 2025, December 31, 2024, and September 30, 2024.

(6) PROPERTY, PLANT AND EQUIPMENT

						Construction in progress and equipment before acceptance inspection	Total
<u>January 1, 2025</u>	<u>Buildings</u>	<u>Machinery and equipment</u>	<u>Transportation equipment</u>	<u>Office equipment</u>	<u>Other equipment</u>		
Cost	\$ 4,309,016	\$ 6,194,785	\$ 29,299	\$ 254,278	\$ 173,026	\$ 194,044	\$ 11,154,448
Accumulated depreciation	(2,074,839)	(4,976,305)	(22,930)	(198,727)	(138,624)	-	(7,411,425)
Accumulated impairment	-	(4,134)	-	-	-	-	(4,134)
	<u>\$ 2,234,177</u>	<u>\$ 1,214,346</u>	<u>\$ 6,369</u>	<u>\$ 55,551</u>	<u>\$ 34,402</u>	<u>\$ 194,044</u>	<u>\$ 3,738,889</u>
<u>For the nine-month period ended September 30, 2025</u>							
At January 1	\$ 2,234,177	\$ 1,214,346	\$ 6,369	\$ 55,551	\$ 34,402	\$ 194,044	\$ 3,738,889
Additions	-	703	-	24	-	46,685	47,412
Reclassified from prepayments for equipment	-	-	-	-	-	59,487	59,487
Reclassified upon completion	8,097	188,253	142	29,706	2,303	(228,501)	-
Reclassified to intangible assets	-	-	-	-	-	(1,278)	(1,278)
Reclassified to other non-current assets - others	-	-	-	-	-	(5,755)	(5,755)
Depreciation charge	(141,141)	(193,196)	(1,469)	(16,249)	(2,754)	-	(354,809)
Disposals — Cost	(1,684)	(36,235)	-	(20,063)	(680)	-	(58,662)
— Accumulated depreciation	778	36,041	-	20,016	612	-	57,447
Reversal of impairment loss	-	63	-	-	-	-	63
Net currency exchange differences	(33,912)	(17,151)	(165)	(830)	(1,321)	(6,087)	(59,466)
At September 30	<u>\$ 2,066,315</u>	<u>\$ 1,192,824</u>	<u>\$ 4,877</u>	<u>\$ 68,155</u>	<u>\$ 32,562</u>	<u>\$ 58,595</u>	<u>\$ 3,423,328</u>
<u>September 30, 2025</u>							
Cost	\$ 4,263,020	\$ 6,305,266	\$ 29,046	\$ 260,034	\$ 166,756	\$ 58,595	\$ 11,082,717
Accumulated depreciation	(2,196,705)	(5,108,371)	(24,169)	(191,879)	(134,194)	-	(7,655,318)
Accumulated impairment	-	(4,071)	-	-	-	-	(4,071)
	<u>\$ 2,066,315</u>	<u>\$ 1,192,824</u>	<u>\$ 4,877</u>	<u>\$ 68,155</u>	<u>\$ 32,562</u>	<u>\$ 58,595</u>	<u>\$ 3,423,328</u>

						Construction in progress and equipment before acceptance inspection	Total
<u>January 1, 2024</u>	Buildings	Machinery and equipment	Transportation equipment	Office equipment	Other equipment		
Cost	\$ 4,249,075	\$ 5,998,911	\$ 26,907	\$ 244,141	\$ 165,103	\$ 77,715	\$ 10,761,852
Accumulated depreciation	(1,875,104)	(4,772,711)	(21,402)	(195,193)	(131,732)	-	(6,996,142)
Accumulated impairment	-	(3,014)	-	-	-	-	(3,014)
	<u>\$ 2,373,971</u>	<u>\$ 1,223,186</u>	<u>\$ 5,505</u>	<u>\$ 48,948</u>	<u>\$ 33,371</u>	<u>\$ 77,715</u>	<u>\$ 3,762,696</u>
<u>For the nine-month period ended September 30, 2024</u>							
At January 1	\$ 2,373,971	\$ 1,223,186	\$ 5,505	\$ 48,948	\$ 33,371	\$ 77,715	\$ 3,762,696
Additions	-	136	-	18	-	45,976	46,130
Reclassified from prepayments for equipment	-	-	-	-	-	201,670	201,670
Reclassified upon completion	25,829	184,834	1,154	14,164	2,967	(228,948)	-
Depreciation charge	(141,562)	(186,687)	(1,277)	(12,938)	(2,537)	-	(345,001)
Disposals — Cost	(9,300)	(40,042)	(351)	(15,224)	(1,069)	-	(65,986)
— Accumulated depreciation	2,046	36,907	351	15,202	998	-	55,504
Net currency exchange differences	30,666	13,817	126	705	1,113	927	47,354
At September 30, 2024	<u>\$ 2,281,650</u>	<u>\$ 1,232,151</u>	<u>\$ 5,508</u>	<u>\$ 50,875</u>	<u>\$ 34,843</u>	<u>\$ 97,340</u>	<u>\$ 3,702,367</u>
Cost	\$ 4,310,459	\$ 6,177,089	\$ 27,990	\$ 246,216	\$ 173,640	\$ 97,340	\$ 11,032,734
Accumulated depreciation	(2,028,809)	(4,941,924)	(22,482)	(195,341)	(138,797)	-	(7,327,353)
Accumulated impairment	-	(3,014)	-	-	-	-	(3,014)
	<u>\$ 2,281,650</u>	<u>\$ 1,232,151</u>	<u>\$ 5,508</u>	<u>\$ 50,875</u>	<u>\$ 34,843</u>	<u>\$ 97,340</u>	<u>\$ 3,702,367</u>

- A. The Group has not capitalised borrowing costs as part of property, plant and equipment for the three-month and nine-month periods ended September 30, 2025 and 2024.
- B. The Group's property, plant and equipment were owner-occupied for the nine-month periods ended September 30, 2025 and 2024.
- C. As of September 30, 2025, December 31, 2024, and September 30, 2024, the Group has not pledged any property, plant and equipment as collateral.

(7) LEASING ARRANGEMENTS—LESSEE

- A. The Group leases land and buildings and structures. Rental contracts are typically made for periods of 50 (including the option to extend the leases) and 2 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions, with no restrictions other than the use of the subject matter of the lease in accordance with relevant laws and regulations.
- B. Short-term leases with a lease term of 12 months or less pertain to office premises and low-value assets pertain to computers.
- C. The carrying amount of right-of-use assets and the depreciation charge are as follows:

	<u>September 30, 2025</u>	<u>December 31, 2024</u>	<u>September 30, 2024</u>
	<u>Carrying amount</u>	<u>Carrying amount</u>	<u>Carrying amount</u>
Land	\$ 669,294	\$ 684,290	\$ 688,527
Buildings and structures	7,177	2,345	-
	<u>\$ 676,471</u>	<u>\$ 686,635</u>	<u>\$ 688,527</u>

For the three-month periods ended September 30,

	<u>2025</u>	<u>2024</u>
	<u>Depreciation charge</u>	<u>Depreciation charge</u>
Land	\$ 3,945	\$ 3,980
Buildings and structures	1,365	335
	<u>\$ 5,310</u>	<u>\$ 4,315</u>

For the nine-month periods ended September 30,

	<u>2025</u>	<u>2024</u>
	<u>Depreciation charge</u>	<u>Depreciation charge</u>
Land	\$ 11,879	\$ 11,921
Buildings and structures	3,409	1,007
	<u>\$ 15,288</u>	<u>\$ 12,928</u>

- D. For the three-month and nine-month periods ended September 30, 2025 and 2024, the Group's additions of right-of-use assets were \$—, \$—, \$8,241 and \$—, respectively; the remeasurements of right-of-use assets were \$—, \$—, \$— and \$61,985, respectively.

E. The information on income and expense accounts relating to lease contracts is as follows:

	For the three-month periods ended September 30,	
	2025	2024
<u>Items affecting profit or loss</u>		
Interest expense on lease liabilities	\$ 1,820	\$ 1,815
Expense on short-term lease contracts	241	220
Expense on leases of low-value assets	876	1,068
For the nine-month periods ended September 30,		
	2025	2024
<u>Items affecting profit or loss</u>		
Interest expense on lease liabilities	\$ 5,476	\$ 5,473
Expense on short-term lease contracts	764	461
Expense on leases of low-value assets	2,343	3,143

F. For the nine-month periods ended September 30, 2025 and 2024, the Group's total cash outflow for leases were \$20,380 and \$18,427, respectively.

(8) IMPAIRMENT OF NON-FINANCIAL ASSETS

- A. For the three-month and nine-month periods ended September 30, 2025 and 2024, the Group recognised the reversal of impairment loss amounting to \$—, \$—, \$63 and \$—, respectively (listed as “Other gains and losses”) as some of the idle machineries were disposed. For details of accumulated impairment, refer to Note 6(6), “Property, plant and equipment”.
- B. The reversal of impairment loss reported by operating segments is as follows:

Segment	For the nine-month periods ended September 30,			
	2025		2024	
	Recognised in profit or loss	Recognised in other comprehensive income	Recognised in profit or loss	Recognised in other comprehensive income
ScinoPharm Taiwan, Ltd.	\$ 63	\$ -	\$ -	\$ -

There was no such situation for the three-month periods ended September 30, 2025 and 2024.

(9) SHORT-TERM BORROWINGS

Type of borrowings	September 30, 2025	Interest rate	Collateral
Bank loans			
Unsecured loans	\$ 139,477	2.60%~2.80%	None

Type of borrowings	December 31, 2024	Interest rate	Collateral
Bank loans			
Unsecured loans	\$ 35,563	2.90%~3.00%	None

Type of borrowings	September 30, 2024	Interest rate	Collateral
Bank loans			
Unsecured loans	\$ 35,704	2.90%~3.00%	None

Refer to Note 6(21), "Finance costs" for interest expense recognised in profit or loss for the three-month and nine-month periods ended September 30, 2025 and 2024.

(10) OTHER PAYABLES

	September 30, 2025	December 31, 2024	September 30, 2024
Accrued salaries and bonuses	\$ 92,680	\$ 96,725	\$ 96,100
Payables on equipment	40,582	154,222	32,035
Accrued employees' compensation and directors' remuneration	13,868	46,723	33,788
Others	167,522	200,521	179,995
	<u>\$ 314,652</u>	<u>\$ 498,191</u>	<u>\$ 341,918</u>

(11) PENSIONS

A. The Company has set up a defined benefit pension plan in accordance with the Labor Standards Law, which applies to all regular employees' service years prior to the enforcement of the Labor Pension Act (the "Act") on July 1, 2005 and service years thereafter of employees who chose to continue to be covered under the pension scheme of the Labor Standards Law after the enforcement of the Act. In accordance with the Company's retirement plan, an employee may retire when the employee either (i) attains the age of 55 with 15 years of service, (ii) has more than 25 years of service, (iii) has reached the age of 65, or (iv) is incapacitated to work (compulsory retirement). The employees earn two units for each year of service for the first 15 years, and one unit for each additional year thereafter up to a maximum of 45 units. Any fraction of a year equal to or more than six months shall be counted as one year of service, and any fraction of a year less than six months shall be counted as half a year. According to the provisions, employees who retired due to their duties shall get additional 20%. Pension payments are based on the number of units earned and the average salary of the last six months prior to retirement. Calculation of average salary is in accordance with the Labor Standards Law of the R.O.C. The

Company contributes monthly an amount equal to 2% of the employees' monthly salaries and wages to the retirement fund deposited with Bank of Taiwan under the name of the independent retirement fund committee. Also, the Company would assess the balance in the aforementioned labor pension reserve account by December 31, every year. If the account balance is not enough to pay the pension calculated by the aforementioned method to the employees expected to qualify for retirement in the following year, the Company will make contribution for the deficit by end of March next year.

- (a) The pension costs under the aforementioned defined benefit pension plan of the Company for the three-month and nine-month periods ended September 30, 2025 and 2024 were \$287, \$272, \$860 and \$817, respectively.
 - (b) Expected contributions to the defined benefit pension plan of the Company for 2025 amount to \$2,762.
- B. As a result of the enforcement of the Act, the Company set up a defined contribution pension plan which took effect on July 1, 2005. The local employees are eligible for the defined contribution plan. For employees who choose to be covered under the pension scheme of the Act, the Company contributes monthly an amount of not less than 6% of the employees' monthly salaries and wages to the employees' individual pension accounts at the Bureau of Labor Insurance. Pensions are paid by monthly installments or in lump sum based on the accumulated balances of the employees' individual pension accounts. The subsidiaries in Mainland China (SciAnda (Changshu) Pharmaceuticals, Ltd., and SciAnda Shanghai Biochemical Technology, Ltd.) are subject to a government sponsored defined contribution plan. In accordance with the related Laws of the People's Republic of China, the subsidiaries in Mainland China contribute monthly 18% of the employees' monthly salaries and wages to an independent fund administered by the government. Other than the monthly contributions, these subsidiaries do not have further obligations. The other subsidiaries, SPT International, Ltd. and ScinoPharm Singapore Pte Ltd., had no employees. For the three-month and nine-month periods ended September 30, 2025 and 2024, the pension costs recognised under the aforementioned defined contribution pension plans were \$10,775, \$10,410, \$32,421 and \$31,047, respectively.

(12) SHARE CAPITAL

- A. Movements in the number of the Company's ordinary shares outstanding are as follows (in thousands of shares):

	<u>For the nine-month periods ended September 30,</u>	
	<u>2025</u>	<u>2024</u>
At January 1 and September 30	<u>790,739</u>	<u>790,739</u>

- B. As of September 30, 2025, the Company's authorised capital was \$10,000,000, and the paid-in capital was \$7,907,392 (790,739 thousand shares) with a par value of \$10 (in dollars) per share. All proceeds from shares issued have been collected.

(13) CAPITAL RESERVES

A. Pursuant to the R.O.C. Company Act, capital reserve arising from paid-in capital in excess of par value on issuance of common stocks and donations shall be exclusively used to cover accumulated deficit or, distribute cash or stocks in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the capital reserve to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. Capital reserve should not be used to cover accumulated deficit unless the legal reserve is insufficient.

B. Movements on the Company's capital reserve are as follows:

	For the nine-month period ended September 30, 2025		
	Share premium	Stock options	Total
At January 1	\$ 1,265,818	\$ 28,871	\$ 1,294,689
Employee stock options forfeited			
- Company	2,494	(2,494)	-
At September 30	<u>\$ 1,268,312</u>	<u>\$ 26,377</u>	<u>\$ 1,294,689</u>
	For the nine-month period ended September 30, 2024		
	Share premium	Stock options	Total
At January 1	\$ 1,265,336	\$ 29,353	\$ 1,294,689
Employee stock options forfeited			
- Company	482	(482)	-
At September 30	<u>\$ 1,265,818</u>	<u>\$ 28,871</u>	<u>\$ 1,294,689</u>

(14) SHARE-BASED PAYMENT – EMPLOYEES' COMPENSATION

A. The Company issued 1.5 million units and 1.5 million units of employee stock options on November 6, 2015 and October 14, 2016, respectively (the 'Grant Date'). The exercise price of the options was set at \$41.65 (in dollars) and \$40.55 (in dollars), respectively, which was based on the closing market price of the Company's common shares on the Grant Dates. Each option gives the holder the right to purchase one share of the Company's common stocks. The exercise price is subject to further adjustments when there is a change in the number of shares of the Company's common stocks, the cash dividend of the common stocks is more than 1.5% of the current price per share or there is a decrease in common stocks caused by capital reduction not due to the retirement of treasury share after the Grant Date. Contract period of the employee stock option plans is 10 years, and options are exercisable in 2 years after the Grant Date.

B. Details of the share-based payment arrangements are as follows:

<u>For the nine-month period ended September 30, 2025</u>		
	Number of options (in thousand units)	Weighted-average exercise price (in dollars)
Options outstanding at beginning of the period	1,128	\$ 36.07
Options forfeited	(186)	36.11
Options outstanding at end of the period	942	35.32
Options exercisable at end of the period	942	35.32
<u>For the nine-month period ended September 30, 2024</u>		
	Number of options (in thousand units)	Weighted-average exercise price (in dollars)
Options outstanding at beginning of the period	1,164	\$ 36.07
Options forfeited	(36)	36.13
Options outstanding at end of the period	1,128	36.07
Options exercisable at end of the period	1,128	36.07

C. The expiry date, exercisable shares and exercise prices of the employee stock options at balance sheet date are as follows:

		<u>September 30, 2025</u>		<u>December 31, 2024</u>	
		No. of stocks	Exercise price (in dollars)	No. of stocks	Exercise price (in dollars)
<u>Grant date</u>	<u>Expiry date</u>	(unit in thousands)	(Note)	(unit in thousands)	(Note)
11.6.2015	11.5.2025	445	\$ 35.06	515	\$ 35.80
10.14.2016	10.13.2026	497	35.55	613	36.30

		<u>September 30, 2024</u>	
		No. of stocks	Exercise price (in dollars)
<u>Grant date</u>	<u>Expiry date</u>	(unit in thousands)	(Note)
11.6.2015	11.5.2025	515	\$ 35.80
10.14.2016	10.13.2026	613	36.30

Note: Exercise price is adjusted according to a specific formula.

D. The fair value of the Group's employee stock options on Grant Date was evaluated using the combination of Hull & White and the Ritchken trinomial option valuation model. Related information is as follows:

Type of arrangement	Grant date	Stock price (in dollars)	Exercise price (in dollars)	Price volatility	Option life	Expected dividends	Interest rate	Fair value per unit (in dollars)
Employee stock options	11.6.2015	\$ 41.65	\$ 41.65	37.63% (Note)	10 years	1.5%	1.2936%	\$ 13.799
Employee stock options	10.14.2016	40.55	40.55	37.20% (Note)	10 years	1.5%	0.9223%	13.171

Note: According to daily returns of the Company's stock for the previous year, the annualised volatility were 37.63% and 37.20%, respectively.

(15) RETAINED EARNINGS

- A. Pursuant to the amended R.O.C. Company Act, the current year's after-tax earnings should be used initially to cover any accumulated deficit; thereafter 10% of the remaining earnings should be set aside as legal reserve until the balance of legal reserve is equal to that of paid-in capital. The legal reserve shall be exclusively used to cover accumulated deficit, to issue new stocks, or to distribute cash to shareholders in proportion to their share ownership. The use of legal reserve for the issuance of stocks or cash dividends to shareholders in proportion to their share ownership is permitted provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company's paid-in capital.
- B. According to the Articles of Incorporation of the Company, since the Company is in a changeable industry environment and the life cycle of the Company is in a stable growth, the appropriation of earnings should consider fund requirements and capital budget to decide how much earnings will be kept or distributed and how much cash dividends will be distributed. According to the Company's Articles of Incorporation, 10% of the annual net income, except for offsetting any loss of prior years and paying all taxes and dues according to laws, after adding items other than net profit after taxes for the year into undistributed surplus earnings of current year, 10% of the remaining shall be set aside as legal reserve. The remaining net income and the unappropriated retained earnings from prior years can be distributed in accordance with a resolution passed during a meeting of the Board of Directors and approved at the stockholders' meeting. Of the amount to be distributed by the Company, stockholders' dividends shall comprise 50% to 100% of the unappropriated retained earnings, and the percentage of cash dividends shall not be less than 30% of dividends distributed.
- C. In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings. The amounts previously set aside by the Company as special reserve on initial application of IFRSs in accordance with Order No. Jin-Guan-Zheng-Fa-Zi Letter No.

1010012865, dated April 6, 2012, shall be reversed proportionately when the relevant assets are used, disposed of or reclassified subsequently. As of September 30, 2025, the amount of special reserve on initial application of IFRSs provided in accordance with the order from Financial Supervisory Committee was \$22,829.

- D. The Company recognised cash dividends distributed to owners amounting to \$237,222 (\$0.3 (in dollars) per share) for the year ended December 31, 2024. On May 28, 2025, the stockholders approved the distribution of cash dividends of \$276,759 (\$0.35 (in dollars) per share) from 2024 earnings.

(16) OTHER EQUITY ITEMS

For the nine-month period ended September 30, 2025			
Unrealised loss			
	Currency translation	on valuation	Total
At January 1	(\$ 28,638)	(\$ 97,539)	(\$ 126,177)
Revaluation	-	725,979	725,979
Currency translation differences			
- Group	(77,748)	-	(77,748)
At September 30	(\$ 106,386)	\$ 628,440	\$ 522,054

For the nine-month period ended September 30, 2024			
Unrealised loss			
	Currency translation	on valuation	Total
At January 1	(\$ 88,156)	(\$ 97,700)	(\$ 185,856)
Revaluation	-	4,591	4,591
Currency translation differences			
- Group	66,099	-	66,099
At September 30	(\$ 22,057)	(\$ 93,109)	(\$ 115,166)

(17) OPERATING REVENUE

- A. Disaggregation of revenue from contracts with customers

The Group derives revenue from the transfer of goods at a point in time and the rendering of services over time in the following major product lines:

For the three-month period ended	API	Injection	Technical	Other	
September 30, 2025	Income	Product	Service	Operating	Total
		Income	Income	Income	
Timing of revenue recognition:					
At a point in time	\$ 576,844	\$ 51,210	\$ -	\$ 4,753	\$ 632,807
Over time	-	-	88,688	-	88,688
	<u>\$ 576,844</u>	<u>\$ 51,210</u>	<u>\$ 88,688</u>	<u>\$ 4,753</u>	<u>\$ 721,495</u>

For the three-month period ended September 30, 2024	API Income	Injection Product Income	Technical Service Income	Other Operating Income	Total
Timing of revenue recognition:					
At a point in time	\$ 577,488	\$ 20,512	\$ -	\$ 49	\$ 598,049
Over time	-	-	126,174	-	126,174
	<u>\$ 577,488</u>	<u>\$ 20,512</u>	<u>\$ 126,174</u>	<u>\$ 49</u>	<u>\$ 724,223</u>
For the nine-month period ended September 30, 2025	API Income	Injection Product Income	Technical Service Income	Other Operating Income	Total
Timing of revenue recognition:					
At a point in time	\$ 1,831,894	\$ 122,175	\$ -	\$ 30,031	\$ 1,984,100
Over time	-	-	171,281	-	171,281
	<u>\$ 1,831,894</u>	<u>\$ 122,175</u>	<u>\$ 171,281</u>	<u>\$ 30,031</u>	<u>\$ 2,155,381</u>
For the nine-month period ended September 30, 2024	API Income	Injection Product Income	Technical Service Income	Other Operating Income	Total
Timing of revenue recognition:					
At a point in time	\$ 2,087,535	\$ 58,991	\$ -	\$ 35,168	\$ 2,181,694
Over time	-	-	188,114	-	188,114
	<u>\$ 2,087,535</u>	<u>\$ 58,991</u>	<u>\$ 188,114</u>	<u>\$ 35,168</u>	<u>\$ 2,369,808</u>

B. The Group has recognised the following revenue-related contract assets and liabilities:

	September 30, 2025	December 31, 2024	September 30, 2024	January 1, 2024
Contract assets - current	<u>\$ 77,480</u>	<u>\$ 29,397</u>	<u>\$ -</u>	<u>\$ -</u>
Contract liabilities - current	<u>\$ 75,940</u>	<u>\$ 119,396</u>	<u>\$ 157,755</u>	<u>\$ 110,967</u>

C. The revenue recognised that was included in the contract liability balance at the beginning of the period amounted to \$29,237, \$6,393, \$85,091 and \$64,416 for the three-month and nine-month periods ended September 30, 2025 and 2024, respectively.

(18) INTEREST INCOME

	For the three-month periods ended September 30,	
	2025	2024
Interest income from bank deposits	<u>\$ 12,009</u>	<u>\$ 15,064</u>
	For the nine-month periods ended September 30,	
	2025	2024
Interest income from bank deposits	<u>\$ 41,125</u>	<u>\$ 45,238</u>

(19) OTHER INCOME

For the three-month periods ended September 30,		
	2025	2024
Dividend income	\$ 25,615	\$ -
Government grants income	472	2,078
Other income	638	298
	<u>\$ 26,725</u>	<u>\$ 2,376</u>
For the nine-month periods ended September 30,		
	2025	2024
Dividend income	\$ 25,615	\$ -
Government grants income	564	2,078
Other income	1,423	2,368
	<u>\$ 27,602</u>	<u>\$ 4,446</u>

(20) OTHER GAINS AND LOSSES

For the three-month periods ended September 30,		
	2025	2024
Net (loss) gain on financial assets/liabilities at fair value through profit or loss	(\$ 9,939)	\$ 1,506
Loss on disposal of property, plant and equipment	(100)	(3,588)
Net currency exchange gain (loss)	13,872	(10,958)
Others	(1,063)	(365)
	<u>\$ 2,770</u>	<u>(\$ 13,405)</u>
For the nine-month periods ended September 30,		
	2025	2024
Net gain (loss) on financial assets/liabilities at fair value through profit or loss	\$ 2,884	(\$ 21,178)
Gain on reversal of impairment loss	63	-
Gain (loss) on disposal of property, plant and equipment	3	(4,278)
Net currency exchange (loss) gain	(40,149)	28,626
Others	(1,881)	(2,448)
	<u>(\$ 39,080)</u>	<u>\$ 722</u>

(21) FINANCE COSTS

For the three-month periods ended September 30,		
	2025	2024
Interest expense:		
Bank loans	\$ 888	\$ 119
Interest on lease liabilities	1,820	1,815
	<u>\$ 2,708</u>	<u>\$ 1,934</u>
For the nine-month periods ended September 30,		
	2025	2024
Interest expense:		
Bank loans	\$ 1,632	\$ 528
Interest on lease liabilities	5,476	5,473
	<u>\$ 7,108</u>	<u>\$ 6,001</u>

(22) EXPENSES BY NATURE

For the three-month period ended September 30, 2025			
	Operating costs	Operating expenses	Total
Employee benefit expenses	\$ 160,006	\$ 87,276	\$ 247,282
Depreciation of property, plant and equipment	102,198	18,099	120,297
Depreciation of right-of-use assets	-	5,310	5,310
Amortisation	878	4,276	5,154
For the three-month period ended September 30, 2024			
	Operating costs	Operating expenses	Total
Employee benefit expenses	\$ 166,166	\$ 78,635	\$ 244,801
Depreciation of property, plant and equipment	99,085	18,042	117,127
Depreciation of right-of-use assets	-	4,315	4,315
Amortisation	680	1,799	2,479
For the nine-month period ended September 30, 2025			
	Operating costs	Operating expenses	Total
Employee benefit expenses	\$ 485,362	\$ 257,787	\$ 743,149
Depreciation of property, plant and equipment	302,262	52,547	354,809
Depreciation of right-of-use assets	-	15,288	15,288
Amortisation	2,817	12,430	15,247

	For the nine-month period ended September 30, 2024		
	<u>Operating costs</u>	<u>Operating expenses</u>	<u>Total</u>
Employee benefit expenses	\$ 499,039	\$ 253,946	\$ 752,985
Depreciation of property, plant and equipment	293,108	51,893	345,001
Depreciation of right-of-use assets	-	12,928	12,928
Amortisation	2,062	4,814	6,876

(23) EMPLOYEE BENEFIT EXPENSES

	For the three-month period ended September 30, 2025		
	<u>Operating costs</u>	<u>Operating expenses</u>	<u>Total</u>
Salaries and wages	\$ 134,042	\$ 73,138	\$ 207,180
Labor and health insurance expenses	11,981	5,673	17,654
Pension costs	7,425	3,637	11,062
Other personnel expenses	6,558	4,828	11,386
	<u>\$ 160,006</u>	<u>\$ 87,276</u>	<u>\$ 247,282</u>

	For the three-month period ended September 30, 2024		
	<u>Operating costs</u>	<u>Operating expenses</u>	<u>Total</u>
Salaries and wages	\$ 140,373	\$ 65,268	\$ 205,641
Labor and health insurance expenses	11,617	5,066	16,683
Pension costs	7,382	3,300	10,682
Other personnel expenses	6,794	5,001	11,795
	<u>\$ 166,166</u>	<u>\$ 78,635</u>	<u>\$ 244,801</u>

	For the nine-month period ended September 30, 2025		
	<u>Operating costs</u>	<u>Operating expenses</u>	<u>Total</u>
Salaries and wages	\$ 405,212	\$ 214,393	\$ 619,605
Labor and health insurance expenses	37,138	17,384	54,522
Pension costs	22,792	10,489	33,281
Other personnel expenses	20,220	15,521	35,741
	<u>\$ 485,362</u>	<u>\$ 257,787</u>	<u>\$ 743,149</u>

	For the nine-month period ended September 30, 2024		
	<u>Operating costs</u>	<u>Operating expenses</u>	<u>Total</u>
Salaries and wages	\$ 420,602	\$ 213,705	\$ 634,307
Labor and health insurance expenses	36,256	16,302	52,558
Pension costs	22,532	9,332	31,864
Other personnel expenses	19,649	14,607	34,256
	<u>\$ 499,039</u>	<u>\$ 253,946</u>	<u>\$ 752,985</u>

- A. According to the Articles of Incorporation of the Company, a ratio of distributable profit of the current year, after covering accumulated losses, shall be distributed as employees' compensation and directors' remuneration. The ratio shall not be lower than 2% for employees' compensation (compensation for grassroots employees shall not be less than 1%) and shall not be higher than 2% for directors' remuneration.
- B. For the three-month and nine-month periods ended September 30, 2025 and 2024, the employees' compensation was accrued at \$1,916, \$3,392, \$12,337 and \$29,916, respectively, while the directors' remuneration was accrued at \$248, \$433, \$1,531 and \$3,872, respectively. The aforementioned amounts were recognised in salary expenses and were estimated and accrued based on the earnings of current period and the percentage specified in the Articles of Incorporation of the Company. The actual amount approved at the Board of Directors' meeting for employees' compensation and directors' remuneration for 2024 was \$46,723, which was the same as the amount recognised in the 2024 financial statements. The employees' compensation was distributed in the form of cash for 2024. Information about the appropriation of employees' compensation and directors' remuneration by the Company as resolved by the Board of Directors will be posted in the "Market Observation Post System" at the website of the Taiwan Stock Exchange.

(24) INCOME TAX

A. Income tax expense

Components of income tax expense:

	<u>For the three-month periods ended September 30,</u>	
	<u>2025</u>	<u>2024</u>
Current income tax:		
Income tax for the period	\$ 16,690	\$ 12,814
Over provision of prior year's income tax	(479)	-
Total current tax	<u>16,211</u>	<u>12,814</u>
Deferred income tax:		
Origination and reversal of temporary differences	(12,479)	(5,980)
Income tax expense	<u>\$ 3,732</u>	<u>\$ 6,834</u>

	<u>For the nine-month periods ended September 30,</u>	
	<u>2025</u>	<u>2024</u>
Current income tax:		
Income tax for the period	\$ 51,486	\$ 58,035
Over provision of prior year's income tax	(96)	(2,967)
Total current tax	<u>51,390</u>	<u>55,068</u>
Deferred income tax:		
Origination and reversal of temporary differences	(23,648)	2,149
Income tax expense	<u>\$ 27,742</u>	<u>\$ 57,217</u>

B. The Company's income tax returns through 2023 have been assessed and approved by the Tax Authority, and there were no disputes existing between the Company and the Authority as of November 3, 2025.

(25) EARNINGS PER SHARE ("EPS")

	<u>For the three-month period ended September 30, 2025</u>		
		Weighted average number of shares outstanding	EPS
	<u>Amount after tax</u>	<u>(shares in thousands)</u>	<u>(in dollars)</u>
<u>Basic earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	<u>\$ 15,446</u>	<u>790,739</u>	<u>\$ 0.02</u>
<u>Diluted earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 15,446	790,739	
Assumed conversion of all dilutive potential ordinary shares			
Employees' stock options	-	-	
Employees' compensation	<u>-</u>	<u>655</u>	
Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	<u>\$ 15,446</u>	<u>791,394</u>	<u>\$ 0.02</u>

For the three-month period ended September 30, 2024			
	Amount after tax	Weighted average number of shares outstanding (shares in thousands)	EPS (in dollars)
<u>Basic earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 27,103	790,739	\$ 0.03
<u>Diluted earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 27,103	790,739	
Assumed conversion of all dilutive potential ordinary shares			
Employees' stock options	-	-	
Employees' compensation	-	1,178	
Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	\$ 27,103	791,917	\$ 0.03
For the nine-month period ended September 30, 2025			
	Amount after tax	Weighted average number of shares outstanding (shares in thousands)	EPS (in dollars)
<u>Basic earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 95,670	790,739	\$ 0.12
<u>Diluted earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 95,670	790,739	
Assumed conversion of all dilutive potential ordinary shares			
Employees' stock options	-	-	
Employees' compensation	-	1,032	
Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	\$ 95,670	791,771	\$ 0.12

	For the nine-month period ended September 30, 2024		
		Weighted average number of shares outstanding (shares in thousands)	EPS (in dollars)
	Amount after tax		
<u>Basic earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 242,008	790,739	\$ 0.31
<u>Diluted earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 242,008	790,739	
Assumed conversion of all dilutive potential ordinary shares			
Employees' stock options	-	-	
Employees' compensation	-	1,471	
Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	\$ 242,008	792,210	\$ 0.31

For the three-month and nine-month periods ended September 30, 2025 and 2024, some abovementioned stock options issued were anti-dilutive; therefore they were not included in the diluted EPS calculation.

(26) SUPPLEMENTAL CASH FLOW INFORMATION

A. Investing activities with partial cash payments:

	For the nine-month periods ended September 30,	
	2025	2024
Purchase of property, plant and equipment	\$ 47,412	\$ 46,130
Add: Beginning balance of payable on equipment (listed as "Other payables")	102,971	56,759
Less: Ending balance of payable on equipment (listed as "Other payables")	(37,298)	(14,214)
Cash paid for acquisition of property, plant and equipment	\$ 113,085	\$ 88,675

	For the nine-month periods ended September 30,	
	2025	2024
Purchase of prepayments for equipment	\$ 48,229	\$ 159,800
Add: Beginning balance of payable on equipment (listed as "Other payables")	51,251	-
Less: Ending balance of payable on equipment (listed as "Other payables")	(3,284)	(17,821)
Cash paid for prepayments for equipment	<u>\$ 96,196</u>	<u>\$ 141,979</u>

B. Operating and investing activities with no cash flow effects:

	For the nine-month periods ended September 30,	
	2025	2024
Inventory reclassified to prepayments	<u>\$ 3,820</u>	<u>\$ -</u>
Property, plant and equipment reclassified to intangible assets	<u>\$ 1,278</u>	<u>\$ -</u>
Property, plant and equipment reclassified to other non-current assets - others	<u>\$ 5,755</u>	<u>\$ -</u>
Prepayments for equipment reclassified to property, plant and equipment	<u>\$ 59,487</u>	<u>\$ 201,670</u>
Prepayments for equipment reclassified to other non-current assets - others	<u>\$ 51,732</u>	<u>\$ -</u>

(27) CHANGES IN LIABILITIES FROM FINANCING ACTIVITIES

For the nine-month period ended September 30, 2025	Short-term borrowings	Lease liabilities	Guarantee deposits received	Liabilities from financing activities-gross
At January 1, 2025	\$ 35,563	\$ 639,980	\$ 3,992	\$ 679,535
Changes in cash flow from financing activities	106,664	(11,797)	(181)	94,686
Impact of changes in foreign exchange rate	(2,750)	-	(113)	(2,863)
Changes in other non-cash items	-	8,241	-	8,241
At September 30, 2025	<u>\$ 139,477</u>	<u>\$ 636,424</u>	<u>\$ 3,698</u>	<u>\$ 779,599</u>

For the nine-month period ended September 30, 2024	Short-term borrowings	Lease liabilities	Guarantee deposits received	Liabilities from financing activities-gross
At January 1, 2024	\$ 32,137	\$ 587,787	\$ 1,297	\$ 621,221
Changes in cash flow from financing activities	2,166 (9,350)	2,974 (4,210)
Impact of changes in foreign exchange rate	1,401	-	72	1,473
Changes in other non-cash items	-	61,985	-	61,985
At September 30, 2024	<u>\$ 35,704</u>	<u>\$ 640,422</u>	<u>\$ 4,343</u>	<u>\$ 680,469</u>

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

The ultimate parent and ultimate controlling party of the Company is Uni-President Enterprises Corp.

(2) Names of related parties and relationship

Names of related parties	Relationship with the Company
Uni-President Enterprises Corp.	Ultimate parent company
President Securities Corp.	Associate of ultimate parent company
President Transnet Corp.	Associate of ultimate parent company
President Tokyo Corp.	Associate of ultimate parent company
Mech-President Corp.	Associate of ultimate parent company
President Chain Store Corp.	Associate of ultimate parent company
President Chain Store Tokyo Marketing Corp.	Associate of ultimate parent company
President Information Corp.	Associate of ultimate parent company
Duskin Serve Taiwan Co., Ltd.	Associate of ultimate parent company
Uni-President Enterprises (China) Investment Corp.	Associate of ultimate parent company
Uni-President Shanghai Pearly Century Co., Ltd.	Associate of ultimate parent company

(3) Significant transactions and balances with related parties

A. Property transactions

	For the nine-month periods ended September 30,	
	2025	2024
Acquisition of property, plant and equipment		
— Ultimate parent company	\$ 41	\$ -
— Associate of ultimate parent company	286	1,017
	<u>\$ 327</u>	<u>\$ 1,017</u>

There was no such situation for the three-month periods ended September 30, 2025 and 2024.

B. Other expenses

		For the three-month periods ended September 30,	
		2025	2024
Management service fees:			
— Ultimate parent company	\$	1	\$ 51
— Associate of ultimate parent company		726	764
	\$	<u>727</u>	<u>815</u>
		For the nine-month periods ended September 30,	
		2025	2024
Management service fees:			
— Ultimate parent company	\$	2,235	\$ 1,963
— Associate of ultimate parent company		2,229	2,285
	\$	<u>4,464</u>	<u>4,248</u>

(4) Key management compensation

		For the three-month periods ended September 30,	
		2025	2024
Salaries and other short-term employee benefits	\$	10,650	\$ 11,344
Post-employment benefits		120	121
Termination benefits		400	400
	\$	<u>11,170</u>	<u>11,865</u>
		For the nine-month periods ended September 30,	
		2025	2024
Salaries and other short-term employee benefits	\$	32,606	\$ 40,176
Post-employment benefits		361	435
Termination benefits		1,200	1,196
	\$	<u>34,167</u>	<u>41,807</u>

8. PLEDGED ASSETS

Details of the Group's assets pledged as collateral are as follows:

Assets	September 30, 2025	December 31, 2024	September 30, 2024	Purpose of collateral
Pledged time deposits (Note)	<u>\$ 29,270</u>	<u>\$ 30,940</u>	<u>\$ 30,940</u>	Performance guarantee, customs duty and guarantee for credit card

Note: Listed as "Other financial assets - non-current".

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS

(1) As of September 30, 2025, December 31, 2024, and September 30, 2024, the Group's remaining balance due for construction in progress and prepayments for equipment were \$15,563, \$43,512 and \$97,955, respectively.

(2) The amounts of endorsements and guarantees for subsidiaries were as follows:

	Nature	September 30, 2025	December 31, 2024	September 30, 2024
SciAnda (Changshu) Pharmaceuticals,	Guarantee for financing amount	\$ -	\$ 179,661	\$ 180,375

As of September 30, 2025, December 31, 2024, and September 30, 2024, the actual amount drawn down for endorsements and guarantees to subsidiaries was \$ —.

10. SIGNIFICANT DISASTER LOSS

None.

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

None.

12. OTHERS

(1) Capital management

The Group's objectives on managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders, to maintain an optimal capital structure, to reduce the cost of capital and to maintain an adequate capital structure to enable the expansion and enhancement of equipment. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return of capital to shareholders, and issue new shares or sell assets to reduce debts.

(2) Financial instruments

A. Financial instruments

For details of the Group's financial instruments by category, refer to Note 6.

B. Risk management policies

- (a) The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, price risk and interest rate risk), credit risk and liquidity risk.
- (b) The Group's treasury identifies, evaluates and hedges financial risks closely with the Group's operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as use of derivative financial instruments and investment of excess liquidity.
- (c) Information about derivative financial instruments that are used to hedge financial risk are provided in Note 6(2), "Financial assets and liabilities at fair value through profit or loss".

C. Significant financial risks and degrees of financial risks

(a) Market risk

I. Foreign exchange rate risk

- (i) The Group operates internationally and is exposed to foreign exchange risk arising from the transactions of the Company and its subsidiaries used in various functional currency, primarily with respect to USD. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities.
- (ii) To manage their foreign exchange risk arising from future commercial transactions and recognised assets and liabilities, entities in the Group are required to hedge their foreign exchange risk exposure using forward foreign exchange contracts. However, the Group does not adopt hedging accounting. Details of financial assets or liabilities at fair value through profit or loss are provided in Note 6(2), “Financial assets and liabilities at fair value through profit or loss”.
- (iii) The Group’s businesses involve some non-functional currency operations (the Company’s and certain subsidiaries’ functional currency: NTD; other subsidiaries’ functional currency: CNY). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

September 30, 2025			
	Foreign currency amount (in thousands)	Exchange rate	Book value (NTD)
(Foreign currency: functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	\$ 14,396	30.45	\$ 438,358
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	726	30.45	22,107
GBP:NTD	99	40.97	4,056
EUR:NTD	47	35.77	1,681
CHF:NTD	40	38.25	1,530

December 31, 2024			
	Foreign currency amount (in thousands)	Exchange rate	Book value (NTD)
(Foreign currency: functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	\$ 19,110	32.79	\$ 626,617
CNY:NTD	8,827	4.492	39,651
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	712	32.79	23,346
GBP:NTD	173	41.19	7,126
EUR:NTD	48	34.14	1,639
JPY:NTD	5,264	0.210	1,105
September 30, 2024			
	Foreign currency amount (in thousands)	Exchange rate	Book value (NTD)
(Foreign currency: functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	\$ 16,303	31.65	\$ 515,990
USD:CNY	319	7.019	10,096
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	571	31.65	18,072
EUR:NTD	104	35.38	3,680

- (iv) As of September 30, 2025 and 2024, if the NTD:USD exchange rate appreciates/depreciates by 5% with all other factors remaining constant, the Group's net profit after tax for the nine-month periods ended September 30, 2025 and 2024 would increase/decrease by \$16,650 and \$19,917, respectively. If the exchange rate of NTD to other currencies had appreciated/depreciated by 5% with all other factors remaining constant, the effect on the Group's net profit after tax for the nine-month periods ended September 30, 2025 and 2024 is immaterial.
- (v) Total exchange gain (loss) including realised and unrealised arising from significant foreign exchange variation on the monetary items held by the Group for the three-month and nine-month periods ended September 30, 2025 and 2024 amounted to \$13,872, (\$10,958), (\$40,149) and \$28,626, respectively.

II. Price risk

- (i) The Group's equity securities, which are exposed to price risk, are the held financial assets and liabilities at fair value through profit or loss and financial assets at fair value through other comprehensive income. To manage its price risk arising from investments in equity securities, the Group diversifies its portfolio and set stop-loss amounts for these instruments. The Group expects no significant market risk.
- (ii) The Group's investments in equity securities comprise equity securities issued by the domestic and foreign companies. The prices of equity securities would change due to the change of the future value of investee companies. If the prices of these equity securities had increase/decrease by 5% with all other variables held constant, other components of equity would have increased/decreased by \$97,606 and \$3,728 for the nine-month periods ended September 30, 2025 and 2024, respectively, as a result of other comprehensive income on equity investments classified as at fair value through other comprehensive income.

III. Cash flow and fair value interest rate risk

- (i) The Group's main interest rate risk arises from short-term borrowings with variable rates and exposes the Group to cash flow interest rate risk. During the nine-month periods ended September 30, 2025 and 2024, the Group's borrowings at variable rate were denominated in CNY.
- (ii) The Group's borrowings are measured at amortised cost. The borrowings are periodically contractually repriced and to that extent are also exposed to the risk of future changes in market interest rates.
- (iii) If the borrowing interest rates had increased/decreased by 10% with all other variables held constant, the effect on post-tax profit for the nine-month periods ended September 30, 2025 and 2024 is immaterial.

(b) Credit risk

- I. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or counterparties of financial instruments on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable based on the agreed terms.
- II. The Group manages its credit risk taking into consideration the entire group's concern. For banks and financial institutions, only independently rated parties with a minimum rating of 'A' are accepted. According to the Group's credit policy, each local entity in the Group is responsible for managing and analysing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the Board of Directors. The utilisation of credit

limits is regularly monitored.

- III. The Group adopts the following assumption under IFRS 9: If the contract payments were past due over 30 days based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition.
- IV. The Group manages its credit risk, whereby if the contract payments are past due over 180 days based on the terms, there has been impairment.
- V. The Group classifies customers' accounts receivable in accordance with the credit rating of the customer and credit risk on trade. The Group applies the simplified approach using the provision matrix to estimate expected credit loss, and use the forecastability to adjust historical and timely information to assess the default possibility of accounts receivable. Movements in relation to the Group applying the simplified approach to provide loss allowance for accounts receivable are as follows:

	For the nine-month periods ended September 30,	
	2025	2024
At January 1	\$ 1,904	\$ 231
Expected credit (gain) loss	(1,790)	1,681
Impact of foreign exchange rate	-	5
At September 30	<u>\$ 114</u>	<u>\$ 1,917</u>

(c) Liquidity risk

- I. Cash flow forecasting is performed by the Group's treasury department which monitors rolling forecasts of the Group's liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities.
- II. The Group has undrawn borrowing facilities amounting to \$4,992,542, \$4,970,318 and \$5,067,660 as of September 30, 2025, December 31, 2024, and September 30, 2024, respectively.
- III. The following table comprises the Group's non-derivative financial liabilities and derivative financial liabilities with gross-amount settlement that are grouped by their maturity. Non-derivative financial liabilities are analysed from the balance sheet date to the contract maturity date, and derivative financial liabilities are analysed from the balance sheet date to the expected maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

<u>September 30, 2025</u>	<u>Less than 1 year</u>	<u>Between 1 and 2 years</u>	<u>Between 2 and 5 years</u>	<u>More than 5 years</u>
Non-derivative financial liabilities:				
Short-term borrowings	\$ 142,010	\$ -	\$ -	\$ -
Accounts payable	112,017	-	-	-
Other payables	314,652	-	-	-
Lease liabilities	23,963	20,148	55,195	703,730
Guarantee deposits received	1,629	2,069	-	-
Derivative financial liabilities:				
Forward exchange contracts	2,107	-	-	-
<u>December 31, 2024</u>	<u>Less than 1 year</u>	<u>Between 1 and 2 years</u>	<u>Between 2 and 5 years</u>	<u>More than 5 years</u>
Non-derivative financial liabilities:				
Short-term borrowings	\$ 36,174	\$ -	\$ -	\$ -
Notes payable	1,211	-	-	-
Accounts payable	80,959	-	-	-
Other payables	498,191	-	-	-
Lease liabilities	19,764	19,422	55,195	717,529
Guarantee deposits received	-	3,992	-	-
Derivative financial liabilities:				
Forward exchange contracts	1,225	-	-	-
<u>September 30, 2024</u>	<u>Less than 1 year</u>	<u>Between 1 and 2 years</u>	<u>Between 2 and 5 years</u>	<u>More than 5 years</u>
Non-derivative financial liabilities:				
Short-term borrowings	\$ 36,581	\$ -	\$ -	\$ -
Notes payable	1,603	-	-	-
Accounts payable	126,966	-	-	-
Other payables	341,918	-	-	-
Lease liabilities	18,398	18,398	55,195	722,128
Guarantee deposits received	-	4,343	-	-

(3) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. The fair value of the Group's investment in private placement of emerging stocks and foreign exchange contracts is included in Level 2.

Level 3: Unobservable inputs for the asset or liability. The fair value of the Group's investment in equity investment without active market is included in Level 3.

B. Financial instruments not measured at fair value

The carrying amounts of cash and cash equivalents, contract assets, accounts receivable, other receivables, guarantee deposits paid, other financial assets - non-current, short-term borrowings, notes payable, accounts payable, other payables and guarantee deposits received are approximate to their fair values.

C. The related information on financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities are as follows:

<u>September 30, 2025</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets:				
<u>Recurring fair value measurements</u>				
Financial assets at fair value through other comprehensive income				
Equity securities	\$ -	\$1,896,398	\$ 55,715	\$1,952,113
Liabilities:				
<u>Recurring fair value measurements</u>				
Financial liabilities at fair value through profit or loss				
Derivative instruments	\$ -	\$ 2,107	\$ -	\$ 2,107
<u>December 31, 2024</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets:				
<u>Recurring fair value measurements</u>				
Financial assets at fair value through other comprehensive income				
Equity securities	\$ -	\$ -	\$ 70,134	\$ 70,134
Liabilities:				
Financial liabilities at fair value through profit or loss				
Derivative instruments	\$ -	\$ 1,225	\$ -	\$ 1,225

September 30, 2024	Level 1	Level 2	Level 3	Total
Assets:				
<u>Recurring fair value measurements</u>				
Financial assets at fair value through profit or loss				
Derivative instruments	\$ -	\$ 1,974	\$ -	\$ 1,974
Financial assets at fair value through other comprehensive income				
Equity securities	\$ -	\$ -	\$ 74,564	\$ 74,564

D. The methods and assumptions the Group used to measure fair value are as follows:

- (a) The fair value of other financial instruments is measured by using valuation techniques or by reference to counterparty quotes. The fair value of financial instruments measured by using valuation techniques can be referred to current fair value of instruments with similar terms and characteristics in substance, discounted cash flow method or other valuation methods, including calculated by applying model using market information available at the consolidated balance sheet date.
- (b) When assessing non-standard and low-complexity financial instruments, for example, debt instruments without active market, interest rate swap contracts, foreign exchange swap contracts and options, the Group adopts valuation technique that is widely used by market participants. The inputs used in the valuation method to measure these financial instruments are normally observable in the market.
- (c) Forward foreign exchange contracts are usually valued based on the current forward exchange rate.

E. For the nine-month periods ended September 30, 2025 and 2024, there was no transfer between Level 1 and Level 2.

F. The following chart is the movement of Level 3 for the nine-month periods ended September 30, 2025 and 2024:

	For the nine-month periods ended September 30,	
	2025	2024
	Equity instrument	Equity instrument
At January 1	\$ 70,134	\$ 69,973
(Loss) gain recognised in other comprehensive income	(14,419)	4,591
At September 30	\$ 55,715	\$ 74,564

For the nine-month periods ended September 30, 2025 and 2024, there was no transfer in (out) of Level 3.

G. The Group's valuation procedures for fair value measurements is categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions, confirming the resource of information is independent, reliable and in line with other resources and represented as the exercisable price, and frequently assess to make any other necessary adjustments to the fair value.

H. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

		<u>Fair value at September 30, 2025</u>	<u>Valuation technique</u>	<u>Significant unobservable input</u>	<u>Range (weighted average)</u>	<u>Relationship of inputs to fair value</u>
Non-derivative equity instrument:						
Unlisted shares	\$	55,715	Net asset value	Discount for lack of marketability	50%	The higher the discount for lack of marketability, the lower the fair value
		<u>Fair value at December 31, 2024</u>	<u>Valuation technique</u>	<u>Significant unobservable input</u>	<u>Range (weighted average)</u>	<u>Relationship of inputs to fair value</u>
Non-derivative equity instrument:						
Unlisted shares	\$	70,134	Net asset value	Discount for lack of marketability	50%	The higher the discount for lack of marketability, the lower the fair value
		<u>Fair value at September 30, 2024</u>	<u>Valuation technique</u>	<u>Significant unobservable input</u>	<u>Range (weighted average)</u>	<u>Relationship of inputs to fair value</u>
Non-derivative equity instrument:						
Unlisted shares	\$	74,564	Net asset value	Discount for lack of marketability	50%	The higher the discount for lack of marketability, the lower the fair value

- I. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurement. If the discount for lack of marketability increased or decreased by 1% for Level 3, the effect on other comprehensive income for the nine-month periods ended September 30, 2025 and 2024 is immaterial.

13. SUPPLEMENTARY DISCLOSURES

According to the current regulatory requirements, the Group is only required to disclose the information for the nine-month period ended September 30, 2025.

(1) Significant transactions information

- A. Loans to others: None.
- B. Provision of endorsements and guarantees to others: Refer to table 1.
- C. Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): Refer to table 2.
- D. Purchases or sales of goods from or to related parties reaching \$100 million or 20% of paid-in capital or more: Refer to table 3.
- E. Receivables from related parties reaching \$100 million or 20% of paid-in capital or more: None.
- F. Significant inter-company transactions during the reporting period: Refer to table 4.

(2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Refer to table 5.

(3) Information on investments in Mainland China

- A. Basic information: Refer to table 6.
- B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: Refer to table 1 and table 4.

14. SEGMENT INFORMATION

(1) General information

The management of the Group has identified the operating segments based on how the Company's Chief Operating Decision-Maker regularly reviews information in order to make decisions. The Chief Operating Decision-Maker manages the Group's business from geographical and functional perspectives. Geographically, the Group focuses on its sales business in the U.S., Europe and Asia. In addition, the Group categorised its business units into manufacture, sales, research and development and investment management functions, and combines its segments that meet the disclosure threshold as "Others".

(2) Segment information

The segment information provided to the Chief Operating Decision-Maker for the reportable segments is as follows:

For the nine-month period ended September 30, 2025				
	ScinoPharm	SciAnda (Changshu)		
	Taiwan, Ltd.	Pharmaceuticals Ltd.	Others	Total
Segment revenue	\$ 2,124,141	\$ 282,454	\$ 12,918	\$ 2,419,513
Revenue from internal customers	15	251,982	12,135	264,132
Revenue from external customers	2,124,126	30,472	783	2,155,381
— API Income	1,806,259	25,635	-	1,831,894
— Injection Product Income	122,175	-	-	122,175
— Technical Service Income	165,661	4,837	783	171,281
— Other Operating Income	30,031	-	-	30,031
Interest income	40,808	222	95	41,125
Depreciation and amortisation	298,125	86,621	598	385,344
Interest expense	5,476	1,632	-	7,108
Income (loss) from segment before income tax	225,397	(101,201)	396	124,592
Segment assets	10,757,769	1,636,095	24,943	12,418,807
Other acquisition of non-current assets	84,018	17,930	40	101,988
Segment liabilities	1,141,127	205,688	973	1,347,788
For the nine-month period ended September 30, 2024				
	ScinoPharm	SciAnda (Changshu)		
	Taiwan, Ltd.	Pharmaceuticals Ltd.	Others	Total
Segment revenue	\$ 2,176,669	\$ 518,626	\$ 12,076	\$ 2,707,371
Revenue from internal customers	9,571	317,323	10,669	337,563
Revenue from external customers	2,167,098	201,303	1,407	2,369,808
— API Income	1,890,615	196,868	52	2,087,535
— Injection Product Income	58,991	-	-	58,991
— Technical Service Income	182,324	4,435	1,355	188,114
— Other Operating Income	35,168	-	-	35,168
Interest income	44,783	319	136	45,238
Depreciation and amortisation	280,726	83,259	820	364,805
Interest expense	5,473	528	-	6,001
Income from segment before income tax	277,175	34,537	1,267	312,979
Segment assets	10,126,488	1,747,161	33,799	11,907,448
Other acquisition of non-current assets	121,954	93,938	18	215,910
Segment liabilities	1,230,305	129,610	9,576	1,369,491

(3) Reconciliation for segment

- A. The sales between segments were at arms' length. The external revenues reported to the Chief Operating Decision-Maker adopt the same measurement basis for revenues in the statement of comprehensive income. The reconciliations of pre-tax income between reportable segments and continuing operations were as follows:

	<u>For the nine-month periods ended September 30,</u>	
	<u>2025</u>	<u>2024</u>
Reportable segments profit before income tax	\$ 124,196	\$ 311,712
Other segments income before income tax	396	1,267
Internal segments transaction elimination	(1,180)	(13,754)
Profit before income tax	<u>\$ 123,412</u>	<u>\$ 299,225</u>

- B. The amount of total assets provided to the Chief Operating Decision-Maker adopts the same measurement for assets in the Group's financial statements. A reconciliation of assets of reportable segments and total assets is as follows:

	<u>September 30, 2025</u>	<u>September 30, 2024</u>
Assets of reportable segments	\$ 12,393,864	\$ 11,873,649
Assets of other operating segments	24,943	33,799
Internal segment transaction elimination	(106,858)	(123,144)
Total assets	<u>\$ 12,311,949</u>	<u>\$ 11,784,304</u>

- C. The amount of total liabilities provided to the Chief Operating Decision-Maker adopts the same measurement for liabilities in the Group's financial statements. A reconciliation of liabilities of reportable segments and total liabilities is as follows:

	<u>September 30, 2025</u>	<u>September 30, 2024</u>
Liabilities of reportable segments	\$ 1,346,815	\$ 1,359,915
Liabilities of other operating segments	973	9,576
Internal segment transaction elimination	(28,785)	(25,093)
Total liabilities	<u>\$ 1,319,003</u>	<u>\$ 1,344,398</u>

ScinoPharm Taiwan, Ltd. and Subsidiaries
Provision of endorsements and guarantees to others
For the nine-month period ended September 30, 2025

Table 1

Expressed in thousands of NTD

Number	Endorser/ guarantor	Party being endorsed/guaranteed Company name	Relationship with the endorser/ guarantor (Note 1)	Limit on endorsements/ guarantees provided for a single party (Note 2)	Maximum outstanding endorsement/ guarantee amount during the period	Outstanding endorsement/ guarantee amount at September 30, 2025	Actual amount drawn down	Amount of endorsements/ guarantees secured with collateral	Ratio of accumulated endorsement/ guarantee amount to net asset value of the endorser/ guarantor company	Ceiling on total amount of endorsements/ guarantees provided (Note 2)	Provision of endorsements/ guarantees by parent company to subsidiary	Provision of endorsements/ guarantees by subsidiary to parent company	Provision of endorsements/ guarantees to the party in Mainland China	Footnote
0	ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	1	\$ 10,992,946	\$ 180,465	\$ -	\$ -	\$ -	-	\$ 10,992,946	Y	N	Y	—

Note 1: The following code represents the relationship with the Company:

1.A company in which the Company directly and indirectly holds 50% of the voting shares.

Note 2: 1.The limit of total amount of endorsement is 50% of the Company's net worth, for 100% directly or indirectly owned subsidiaries, the maximum amount is 100% of its net worth.

The limit of total amount of the Group's endorsement and guarantee is 100% of the Group's net worth.

2.For any endorsement or guarantee provided by the Company due to business dealings, the amount of endorsement or guarantees shall be limited to the business dealing amount of the most recent year or the current year.

The business dealing amount is product purchase or sale amount between the entities, whichever is higher.

Note 3: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the consolidated financial statements (CNY:NTD 1:4.27).

ScinoPharm Taiwan, Ltd. and Subsidiaries

Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures)

September 30, 2025

Table 2

Expressed in thousands of NTD

Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account	As of September 30, 2025				Footnote
				Number of shares	Book value	Ownership (%)	Fair value	
ScinoPharm Taiwan, Ltd.	Stocks:							
	HANDA PHARMACEUTICALS, INC.	The Company is a director of HANDA PHARMACEUTICALS, INC.	Financial assets at fair value through other comprehensive income - non-current	17,000,000	\$ 1,896,398	10.71%	\$ 1,896,398	—
	Tanvex Biologics, Inc.	The Company is a director of Tanvex Biologics, Inc.	Financial assets at fair value through other comprehensive income - non-current	28,800,000	55,715	16.84%	55,715	—

ScinoPharm Taiwan, Ltd. and Subsidiaries

Purchases or sales of goods from or to related parties reaching \$100 million or 20% of paid-in capital or more

For the nine-month period ended September 30, 2025

Table 3

Expressed in thousands of NTD

Purchaser/seller	Counterparty	Relationship with the counterparty	Transaction				Differences in transaction terms compared to third party transactions		Notes/accounts receivable (payable)		Footnote
			Purchases (sales)	Amount	Percentage of total purchases (sales)	Credit term	Unit price	Credit term	Balance	Percentage of total notes/accounts receivable (payable)	
ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	Subsidiary	Purchases	\$ 255,744	39%	Closes its accounts 90 days from the end of each month	\$ -	—	(\$ 20,948)	(16%)	—
SciAnda (Changshu) Pharmaceuticals, Ltd.	ScinoPharm Taiwan, Ltd.	The Company	(Sales)	(255,744)	(91%)	Closes its accounts 90 days from the end of each month	-	—	20,948	44%	—

ScinoPharm Taiwan, Ltd. and Subsidiaries
Significant inter-company transactions during the reporting period
For the nine-month period ended September 30, 2025

Table 4

Expressed in thousands of NTD

Number (Note 2)	Company name	Counterparty	Relationship (Note 3)	Transactions		Transaction terms	Percentage of consolidated total operating revenues or total assets (Note 4)
				General ledger account	Amount		
0	ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	1	Purchases	\$ 255,744	Closes its accounts 90 days from the end of each month	12%
			1	Accounts Payable	20,948	—	—

Note 1: Significant inter-company transactions during the reporting periods are not disclosed since these were corresponding transactions. Only transactions over NT\$10 million are material.

Note 2: The numbers filled in for the transaction company in respect of inter-company transactions are as follows:

(1) Parent company is '0'.

(2) The subsidiaries are numbered in order starting from '1'.

Note 3: Relationship between transaction company and counterparty is classified into the following three categories:

(1) Parent company to subsidiary.

(2) Subsidiary to parent company.

(3) Subsidiary to subsidiary.

Note 4: Regarding percentage of transaction amount to consolidated total operating revenues or total assets, it is computed based on period-end balance of transaction to consolidated total assets for balance sheet accounts and based on accumulated transaction amount for the period to consolidated total operating revenues for income statement accounts.

Note 5: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the consolidated financial statements (CNY:NTD 1:4.27 ; USD:NTD 1:30.45).

ScinoPharm Taiwan, Ltd. and Subsidiaries

Names, locations and other information of investee companies (not including investees in Mainland China)

For the nine-month period ended September 30, 2025

Table 5

Expressed in thousands of NTD

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at September 30, 2025			Net profit of the investee for the nine-month period ended September 30, 2025	Investment income recognised by the Company for the nine-month period ended September 30, 2025	Footnote
				Balance as at September 30, 2025	Balance as at December 31, 2024	Number of shares	Ownership (%)	Book value			
ScinoPharm Taiwan, Ltd.	SPT International, Ltd.	Tortola, British Virgin Islands	Professional investment	\$ 3,614,585	\$ 3,614,585	118,524,644	100%	\$ 1,376,068	(\$ 100,860)	(\$ 102,040)	Subsidiary
	ScinoPharm Singapore Pte Ltd.	Singapore	Professional investment	-	-	2	100%	235	16	16	Subsidiary

ScinoPharm Taiwan, Ltd. and Subsidiaries

Information on investments in Mainland China — Basic information

For the nine-month period ended September 30, 2025

Table 6

Expressed in thousands of NTD

Investee in Mainland China	Main business activities	Paid-in capital	Investment method	Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2025	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the nine-month period ended September 30, 2025		Accumulated amount of remittance from Taiwan to Mainland China as of September 30, 2025	Net income of investee for the nine-month period ended September 30, 2025	Ownership held by the Company (direct or indirect)	Investment income recognised by the Company for the nine-month period ended September 30, 2025	Book value of investments in Mainland China as of September 30, 2025	Accumulated amount of investment income remitted back to Taiwan as of September 30, 2025	Footnote
					Remitted to Mainland China	Remitted back to Taiwan							
SciAnda (Changshu) Pharmaceuticals, Ltd.	Research, development, and manufacture of API and new drugs, sales of self-produced products, etc.	\$ 3,546,843	(Note 1)	\$ 3,538,453	\$ -	\$ -	\$ 3,538,453	(\$ 101,201)	100%	(\$ 101,201)	\$ 1,430,407	\$ -	Subsidiary (Note 2)
SciAnda Shanghai Biochemical Technology, Ltd.	Import, export and sales of API and intermediates, etc.	36,534	(Note 1)	36,534	-	-	36,534	707	100%	707	20,837	-	Subsidiary (Note 3)
<u>Company name</u>	<u>Accumulated amount of remittance from Taiwan to Mainland China as of September 30, 2025</u>	<u>Investment amount approved by the Investment Commission of the Ministry of Economic Affairs (MOEA)</u>	<u>Ceiling on investments in Mainland China imposed by the Investment Commission of MOEA (Note 4)</u>										
ScinoPharm Taiwan, Ltd.	\$ 3,612,254	\$ 3,612,254	\$ 6,595,768										

Note 1: Indirect investment in Mainland China through a company set up in a third region, SPT International, Ltd.

Note 2: The investment income recognised by the Company for the nine-month period ended September 30, 2025 was based on reviewed financial statements of investee companies as of and for the nine-month period ended September 30, 2025.

Note 3: The investment income recognised by the Company for the nine-month period ended September 30, 2025 was based on unreviewed financial statements of investee companies as of and for the nine-month period ended September 30, 2025.

Note 4: The ceiling amount is 60% of the higher of net worth or consolidated net worth.

Note 5: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the financial statements (USD:NTD 1:30.45).